A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4–6 μg/kg) in patients with major depressive disorder

Overview of attention for article published in Trials, February 2020

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 52 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 1 citation of this research output.

1

The most recent citing publication is shown below. View this citation on Dimensions.

Chapter 7 Development of new rapid-action treatments in mood disorders

Book chapter (January 2021)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.